Cutting-Edge Research Funded Through FDA's Advancing Regulatory Science Broad Agency Announcement (BAA)
To spur innovation in the field of regulatory science FDA funds extramural research using various contract mechanisms and grants to address broad Agency challenges within FDA's scientific priority areas.
Since 2012, FDA has been soliciting proposals to advance the state of the art within these areas through a specialized contract mechanism known as FDA's Broad Agency Announcement (BAA). FDA's BAA makes it possible for us to solicit innovative ideas and approaches to developing and evaluating FDA-regulated products by tapping into external knowledge and infrastructure in areas where FDA has limited expertise or capacities. The proposals solicited from industry, academia, and other government agencies enable us to better understand the breath of innovative scientific and technical solutions available to solve difficult regulatory science problems.
Descriptions of FDA BAA-funded research projects, their goals, and how they're addressing regulatory science challenges within FDA's scientific priority areas are found below.
Highlights of Extramural BAA Research
- Priority Area 1: Modernize Toxicology to Enhance Product Safety
- Priority Area 2: Stimulate Innovation in Clinical Trials
- Priority Area 3: Support New Approaches to Improve Product Manufacturing and Quality
- Priority Area 4: Ensure FDA Readiness to Evaluate Emerging Technologies
- Priority Area 5: Harness Diverse Data through Information Sciences to Improve Health Outcomes
- Priority Area 6: Implement a New Prevention-Based Food Safety System
- Priority Area 7: Facilitate Development of Medical Countermeasures to Protect National Health and Security
- Priority Area 8: Strengthen Social and Behavioral Science to Promote Informed Decision-Making About FDA-Regulated Products
- Priority Area 9: Strengthening the Global Product Safety Net